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Abstract
Background The purpose of this study was to evaluate the
clinical usefulness of open lung biopsy (OLB) in patients
undergoing mechanical ventilation for diffuse pulmonary
infiltrates of unknown etiology.
Methods This was a 10-year retrospective study in a 10-bed
medical intensive care unit. The medical records of 36 ventilator-
dependent patients who underwent OLB for the diagnosis of
unknown pulmonary infiltrates from 1994 to 2004 were
reviewed retrospectively. Data analyzed included demographic
data, Charlson age–comorbidity score, number of organ
dysfunctions, Acute Physiology and Chronic Health Evaluation
(APACHE) II, Simplified Acute Physiology Score (SAPS) II,
Sequential Organ Failure Assessment (SOFA) score, ventilation
variables, and radiological patterns. Diagnostic yield, effect on
subsequent treatment changes, and complications of OLB were
also assessed.
Results A specific clinico-pathologic diagnosis was obtained
for 31 patients (86%). The most common diagnoses were
interstitial pneumonia (n  = 17, including 8 acute interstitial
pneumonia) and viral pneumonia (n  = 4). Therapeutic
modifications were made in 64% of patients. Patients who
received OLB less than 1 week after initiation of mechanical
ventilation were more likely to survive (63% versus 11%; P =
0.018). There were no major complications associated with the
procedure. Factors independently associated with survival were
the Charlson age-comorbidity score, number of organ
dysfunction and the PaO2/FiO2 ratio on the day of the OLB.
Conclusion OLB can provide a specific diagnosis in many
ventilator-dependent patients with undiagnosed pulmonary
infiltrate. Early OLB seems to be useful in critically ill patients
with isolated respiratory failure.
AIP = acute interstitial pneumonia; APACHE II = Acute Physiologic and Chronic Health Evaluation II; ARDS = acute respiratory distress syndrome; 
BAL = bronchoalveolar lavage; CCS = Charlson age–comorbidity score; CI = confidence interval; CMV = cytomegalovirus; ICU = intensive care unit; 
OLB = open lung biopsy; PEEP = positive end-expiratory pressure; SAPS = Simplified Acute Physiology Score; SOFA = Sequential Organ Failure 
Assessment; SOFAadm = SOFA score on the day of ICU admission; SOFAmax = maximum score before the OLB; SOFAolb = SOFA score on the day 
of OLB.Critical Care    Vol 11 No 4    Lim et al.
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Introduction
The development of progressive pulmonary infiltrates in a
patient with respiratory failure is a challenging situation for the
clinician. Although open lung biopsy (OLB) remains the gold
standard for the diagnosis of parenchymal lung disease [1-3],
it is unclear whether the results obtained from an OLB are truly
beneficial to these critically ill patients. Whereas some authors
[2,4,5] have noted that OLB is safe as well as diagnostically
useful, permitting the institution of appropriate therapy, some
[6,7] argue against the usefulness of OLB because it may be
associated with substantial morbidity and mortality. Because
of these potential harmful effects, many clinicians have been
reluctant to perform OLB in patients who are already ventila-
tor-dependent. A recent study by Papazian and colleagues [8]
demonstrated that OLB improved the survival of patients with
unresolving acute respiratory distress syndrome (ARDS) when
biopsy findings were contributory. However, whether OLB is
helpful in patients with diffuse lung infiltrates of unknown etiol-
ogy who are sick enough to warrant ventilator therapy is still
controversial. This study was therefore undertaken to assess
the usefulness and safety of OLB and to identify the prognos-
tic factors associated with survival in ventilator-dependent
patients with diffuse pulmonary infiltrates of unknown origin.
Materials and methods
We conducted a retrospective review of the clinical records of
patients admitted to an adult medical intensive care unit (ICU)
from October 1994 to October 2004 at Samsung Medical
Center. The inclusion criteria were patients with respiratory
failure who underwent OLB as a result of undiagnosed diffuse
pulmonary infiltrates while receiving mechanical ventilatory
support. Patients who did not need mechanical ventilation or
patients who started ventilatory support after OLB were
excluded. Over the period examined, 513 surgical lung biop-
sies were performed for diagnostic purposes at our institution.
For surgical lung biopsy, elective video-assisted thoraco-
scopic surgery was used in 381 patients (74%), and OLB via
minithoracotomy was conducted in 133 (26%). In all, 42
patients underwent surgical lung biopsy for respiratory failure
of unknown etiology. Six patients were excluded because they
were not on mechanical ventilatory support at the time of the
procedure, and 36 patients met our inclusion criteria. None of
the patients included in this study underwent video-assisted
thoracoscopic surgery as the method of lung biopsy.
The medical records from the 36 cases above were analyzed
for the following data: demographic data, body mass index,
comorbidities, time from mechanical ventilation to OLB, radio-
logical findings, ventilation variables including the PaO2/FiO2
ratio, the positive end-expiratory pressure (PEEP), and compli-
ance; in addition, severity scores such as Simplified Acute
Physiology Score (SAPS) II, Acute Physiology and Chronic
Health Evaluation (APACHE) II and Sequential Organ Failure
Assessment (SOFA) score were analyzed. The SOFA score
on the day of ICU admission (SOFAadm), on the day of OLB
(SOFAolb), and the maximum score before the OLB (SOFAmax)
were assessed. The number of organ dysfunctions repre-
sented the number of organs that scored more than 2 points
on the SOFA score. We also collected data on previous diag-
nostic studies and their results, preoperative therapeutic
measures, pathology, perioperative complications, the effect
of OLB on patient management, and the resultant outcome at
ICU discharge. Life-threatening major complication was
defined as the occurrence of death, myocardial infarction, or
stroke within 48 hours of surgery. Documented hypoxia (arte-
rial oxygen saturation less than 90%), hypotension or arrhyth-
mia requiring intervention during the procedure was recorded.
Prolonged air leakage for more than 1 week, wound infection,
bleeding events or any other complications thought to be
directly related to the procedure were also documented. Over-
all comorbidity was assessed with the Charlson age–comor-
bidity score (CCS) [9].
Our typical OLB protocol was as follows. All OLBs were con-
ducted in the operating room under general anesthesia by
means of anterior minithoracotomy. Sites for pulmonary biopsy
were selected before surgery by a thorough review of chest
radiographs and computed tomography studies. After multiple
wedge biopsies, drainage of the pleural space was performed
with a chest tube. Generally, these tubes were removed as
soon as possible if no air leak was present. The operative time
including anesthesia averaged about 1 hour. The lung biopsy
specimens were submitted for bacterial, fungal, acid-fast
bacillus and viral cultures as well as histological examination.
The final diagnosis was made on the basis of a correlation of
the clinical and pathological findings.
Statistical analysis was performed with SPSS v.13.0 package
for Windows (SPSS Inc., Chicago, IL, USA). Results are
expressed as mean ± SD. Survivors and non-survivors were
compared by using the independent-sample t test for continu-
ous variables, and the χ2 test or Fisher's exact test for categor-
ical variables. Univariate analysis was performed and a relative
risk with a 95% confidence interval (CI) was determined. To
assess the factors related to survival, multiple-logistic-regres-
sion analysis was performed, with ICU discharge as the
dependent variable. For all statistical tests used, P < 0.05 was
considered significant.
Results
Patient characteristics before OLB
Characteristics of patients are shown in Table 1. Of the 36
patients enrolled in the study, 25 were male (69%) and 11
were female (31%), with a mean age of 58.5 years (range 20
to 77). The mean CCS was 2.6 (range 0 to 7). The mean
number of organ dysfunctions was 2 (range 1 to 3), SOFAadm
was 5 (range 2 to 12) and the PaO2/FiO2 ratio was 119.5
(range 53 to 267). The median time from mechanical ventila-
tory support to OLB was 4 days (range 1 to 23). Preexisting
comorbid diseases were found in 19 patients (53%).Available online http://ccforum.com/content/11/4/R93
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Preoperative diagnostic procedures and therapeutic 
measures
Preoperative fiberoptic bronchoscopic examination and bron-
choalveolar lavage (BAL) was performed in 31 patients (86%).
BAL revealed positive staining for acid-fast bacilli in two
patients who were already receiving anti-tuberculous medica-
tion for previously diagnosed tuberculosis and were undergo-
ing diagnostic study for progressive lung infiltrates while on
adequate anti-tuberculous medications. Two other patients
had progressive hemorrhagic BAL consistent with diffuse
alveolar hemorrhage. In the other cases the BAL was not help-
ful. Of the radiological studies, diffuse ground glass opacity
alone or combined with consolidation was the predominant
radiological finding in most of the patients (28/36; 78%).
At the time of OLB, all 36 patients were receiving empirical
antibiotic treatment. Eleven patients were on antibiotics only
but the rest were receiving combination therapy with one or
more agents: 18 were receiving steroids, 4 antiviral agents, 3
anti-tuberculous medication and 2 antifungal drugs.
Results of open lung biopsy and effect on patient 
management or outcome
A specific clinico-pathologic diagnosis as a cause of progres-
sive pulmonary infiltrates was established in 31 patients (86%)
after OLB. The specific clinico-pathologic diagnosis based on
the OLB is shown in Table 2. The most common diagnosis
obtained was interstitial pneumonia (n = 17). Fifteen patients
were idiopathic and two had secondary interstitial pneumonia.
Idiopathic interstitial pneumonia included acute interstitial
pneumonia (AIP) (n = 8), cryptogenic organizing pneumonia (n
= 3), acute exacerbation of usual interstitial pneumonia (n = 3)
and nonspecific interstitial pneumonia group 3 (n = 1). AIP
was finally diagnosed after ruling out other factors that could
cause diffuse alveolar damage. Secondary interstitial pneumo-
nia included one patient with non-tuberculous mycobacterium-
associated bronchiolitis obliterans organizing pneumonia and
one with dermatomyositis-associated acute pneumonitis. The
most common alternative diagnosis other than interstitial
pneumonia was viral pneumonia (n = 4), including two cases
of cytomegalovirus (CMV) and another two cases of adenovi-
rus pneumonia. Two patients each had drug toxicity due to
chemotherapeutic agents, miliary tuberculosis and idiopathic
pauci-immune pulmonary capillaritis. Other diagnoses
included cholesterol crystal embolism, culture-negative
bacterial pneumonia, diffuse panbronchiolitis, and metastatic
cancer.
Twenty-three patients (64%) were able to change their ther-
apy on the basis of the OLB results. Drug changes usually
involved the initiation of steroids (n = 15) or antiviral agents (n
= 3). Withdrawal of unnecessary medication was possible in
two patients. The percentage of patients who received thera-
Table 1
Assessment of patient characteristics on admission and on the 
day of open lung biopsy
Characteristic On admission to ICU On day of OLB
Age, years 58.5 (20–77)
Sex
Male 25 (69)
Female 11 (31)
Smoking, pack-years 20 (0–80)
CCS 2.6 (0–7)
APACHE II score 17 (7–27)
SAPS II score 35 (22–65)
SOFA score 5 (2–12) 5 (1–12)
No. of organ dysfunctions 2 (1–3) 2 (1–3)
PaO2/FiO2 ratio 119.5 (53–267) 158.6 (52–320)
PEEP, cmH2O 10 (5–18) 10 (5–18)
Compliance, ml/cmH2O 14.9 (5.1–36.3) 14.0 (5.2–39.3)
Data are presented as mean (range) or n (%). CCS, Charlson age–
comorbidity score; APACHE II, Acute Physiologic and Chronic 
Health Evaluation II; ICU, intensive care unit; OLB, open lung biopsy; 
PEEP, positive end-expiratory pressure; SAPS, Simplified Acute 
Physiology Score; SOFA, Sequential Organ Failure Assessment.
Table 2
Specific clinico-pathologic diagnosis obtained from 31 patients
Diagnosis No. of patients
Idiopathic interstitial pneumonia 15
Acute interstitial pneumonia 8
Cyptogenic organizing pneumonia 3
Acute exacerbation of usual interstitial 
pneumonia
3
Nonspecific interstitial pneumonia group 3 1
Secondary interstitial pneumonia 2
Non-tuberculous mycobacterium-associated 
BOOP
1
Dermatomyositis-associated acute pneumonitis 1
Viral pneumonia 4
Cytomegalovirus pneumonia 2
Adenovirus pneumonia 2
Miliary tuberculosis 2
Chemotherapy drug toxicity 2
Idiopathic pauci-immune pulmonary capillaritis 2
Diffuse panbronchiolitis 1
Cholesterol crystal embolism 1
Acute necrotizing pneumonia 1
Metastatic cancer 1
BOOP, bronchiolitis obliterans organizing pneumonia.Critical Care    Vol 11 No 4    Lim et al.
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peutic modifications was not different between survivors and
non-survivors.
Complications
Twenty patients (56%) had complications that may have been
related to OLB. Prolonged air leakage was a predominant
complication present in 15 patients (42%). We noted another
five cases of intraoperative complications (14%), including
four cases of transient hypotension and one of transient hypo-
tension with bigeminy requiring lidocaine treatment. However,
there were no life-threatening complications associated with
the procedure. There was no statistically significant factor that
predicted the occurrence of complication of OLB (data not
shown).
Comparison between survivors and non-survivors
The overall mortality rate in the ICU for this patient population
was 50%. Table 3 shows a comparison of the clinical charac-
teristics between survivors and non-survivors. There were no
significant differences in a variety of measures including age,
sex, body mass index, smoking history, respiratory symptom
duration, incidence of OLB complications, immune status,
SAPS II score, APACHE II score, time to OLB, serum albumin,
and serum glucose.
However, the CCS in the non-survivors (3.2 ± 2.1; mean ±
SD) was significantly higher than in the survivors (1.9 ± 1.3, P
= 0.030). Severity and ventilation variables that differed signif-
icantly between the two groups were SOFAolb, SOFAmax,
PaO2/FiO2 ratio, and the number of organ dysfunctions on the
day of the OLB. Although the mean time from mechanical ven-
tilation to OLB was not different between the two groups,
more patients (17/18) in the survivor group received OLB dur-
ing the early phase, within 1 week of mechanical ventilation,
than those in the non-survivor group (10/18, P = 0.018).
Prognostic factors associated with outcome
In univariate analysis, a higher CCS, an increased number of
organ dysfunctions, a higher SOFAolb  score, and a lower
PaO2/FiO2 ratio on the day of the OLB was significantly asso-
ciated with death (Table 4). A multiple logistic regression anal-
ysis showed that a higher CCS (OR 1.74; 95% CI 1.002 to
3.01), an increased number of organ dysfunctions (OR 5.24;
95% CI 1.11 to 24.72), and a lower PaO2/FiO2 ratio on the
day of the OLB (OR 0.98; 95% CI 0.957 to 0.996) were asso-
ciated with mortality (Table 5).
Discussion
The major findings of this study are that OLB is an feasible
diagnostic option even in these critically ill patients and that
comorbidity, SOFA score, and PaO2/FiO2 ratio on the day of
the OLB were strong predictors of mortality in these patients.
Moreover, although not statistically significant on multivariate
analysis, the early, rather than late, use of OLB seems to have
a survival advantage.
When a patient is intubated and mechanical ventilation is initi-
ated as a result of respiratory failure of unknown etiology, the
clinician is faced with a difficult decision. An invasive
diagnostic test such as OLB can be considered but it is not
clear which patient subset will benefit from this potentially
harmful procedure. In the literature some reports [5,7,10] have
looked into the utility of OLB in patients with respiratory failure,
but these studies included significant number of patients who
were not receiving mechanical ventilatory care and were thus
less sick at the time of the biopsies. We therefore performed
this study to assess the utility and prognostic factors associ-
ated with OLB in patients who were already on mechanical
ventilators at the time of the surgical procedure.
One large series of OLB in mechanically ventilated critically ill
patients was recently published by Papazian and colleagues
[8]. However, the patient population in that study was different
from that in this study. The patients in that study all had under-
lying etiologies for ARDS and underwent OLB only when the
lung infiltrates did not resolve. This is a clearly different clinical
scenario from that of this study, in which the patients under-
went OLB because the cause of lung infiltrate and respiratory
failure was unclear. This is reflected by the time of OLB after
the initiation of mechanical ventilation, which was a median of
11 days in the study by Papazian and colleagues but only 4
days in our patients.
In this study, a specific clinico-pathologic diagnosis was made
in 86% of patients who underwent OLB while on mechanical
ventilation before biopsy. In addition, therapeutic changes
were made in about two-thirds of patients without life-threat-
ening procedure-related complications. The reported specific
diagnostic rate of OLB has varied from 46% [10] to 100%
[11]. This discrepancy can be partly explained by the definition
for specific diagnosis used in the study. In studies with a high
diagnostic rate, pathologic findings consistent with interstitial
pneumonitis or alveolitis were regarded as specific diagnoses
[11], whereas in studies with a low diagnostic rate these find-
ings were regarded as nonspecific [10]. In the patients in the
present study, the specific diagnosis was made in 86% of the
biopsied patients by carefully correlating clinical findings with
microbiologic and pathologic findings using established crite-
ria, including those for interstitial lung diseases [12]. For exam-
ple, a pathologic finding of diffuse alveolar damage was critical
for the final diagnosis of acute interstitial pneumonia in
patients with progressive pulmonary infiltrate who did not have
positive microbiologic findings and had no history of exposure
to other causes of diffuse alveolar damage.
The role of CMV infection in critically ill patients is still unclear.
There are several reports of a high incidence of CMV pneumo-
nia in critically ill patients even in those without overt immuno-
deficiences [8,13-15]. The relatively high incidence of CMV
infection may be explained by the fact that noninvasive diag-
nostic modalites such as shell-vial culture and CMV pp65 anti-Available online http://ccforum.com/content/11/4/R93
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genemia have low sensitivity. Although the reported incidence
of CMV infection in patients in the ICU showed inconsistent
results, our result (6%) was much lower than in a recent report
by Papazian and colleagues [8], who demonstrated a high inci-
dence of CMV infection in 30/57 (53%) OLB in unresolving
patients with ARDS. It might be that CMV reactivation requires
time and the timing of lung biopsies, which was early in the
present study (median 4 days versus median 11 days for
Papazian and colleagues), might have influenced the results.
Further prospective studies are needed to define the clinical
significance of CMV and to assess the role of preemptive
treatment of antiviral agents.
Table 3
A comparison between survivors and non-survivors
Characteristic Survivor group (n = 18) Non-survivor group (n = 18) P
Age, years 54.5 ± 14.7 57.3 ± 15.2 0.580
Sex
Male 11 (61.1) 14 (77.8) 0.471
Female 7 (38.9) 4 (22.2)
BMI, kg/m2 22.9 ± 2.3 21.7 ± 3.1 0.283
Smoking, pack-years 21.8 ± 23.6 19.9 ± 20.7 0.873
Duration of symptom, days 21.7 ± 33.5 15.2 ± 13.1 0.888
CCS 1.9 ± 1.3 3.2 ± 2.1 0.030
SAPS II score 35.2 ± 9.3 37.6 ± 7.9 0.425
APACHE II score 16.9 ± 5.4 17.6 ± 4.9 0.700
Time to OLB, days 3.8 ± 2.0 6.8 ± 6.4 0.061
OLB time, early/late 17/1 10/8 0.018
Immunocompromised status 3 (17) 7 (39) 0.137
OLB complication 8 (44) 12 (67) 0.180
Ventilation duration, days 14.9 ± 15.5 19.9 ± 12.0 0.282
Number of organ dysfunctions
On MICU admission 1.5 ± 0.6 1.7 ± 0.7 0.308
On day of OLB 1.5 ± 0.6 2.0 ± 0.8 0.039
SOFA score
On MICU admission 5.3 ± 2.5 6.2 ± 2.3 0.249
On day of OLB 4.3 ± 2.1 6.7 ± 2.7 0.005
Maximum 6.1 ± 2.7 8.1 ± 2.9 0.042
PaO2/FiO2ratio
On MICU admission 131.3 ± 37.1 118.9 ± 55.9 0.439
On day of OLB 190.6 ± 67.6 135.4 ± 57.4 0.012
PEEP, cmH2O
On MICU admission 10.2 ± 3.1 11.3 ± 4.2 0.381
On day of OLB 9.4 ± 4.3 11.3 ± 2.4 0.112
Compliance, ml/cmH2O
On MICU admission 16.7 ± 7.7 15.8 ± 5.5 0.703
On day of OLB 17.1 ± 8.4 15.5 ± 7.5 0.550
Data are presented as mean ± SD or n (%). BMI, body mass index; CCS, Charlson age–comorbidity score; SAPS, Simplified Acute Physiology 
Score; APACHE II, Acute Physiologic and Chronic Health Evaluation II; OLB, open lung biopsy; early OLB, OLB within 1 week of mechanical 
ventilation; MICU, medical intensive care unit; SOFA, Sequential Organ Failure Assessment; PEEP, positive end-expiratory pressure.Critical Care    Vol 11 No 4    Lim et al.
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The low incidence of infectious causes in immunocompro-
mised populations is intriguing. In this study, 10 immunocom-
promised patients were included (5 with hematologic
malignancies, 2 with lung cancer, 1 with systemic lupus ery-
thematosus, and 2 with chronic steroid use), and infectious eti-
ologies were found only 2 patients. This result suggests that
the simple use of empirical therapy against infectious organ-
isms might not be enough and that invasive diagnostic tests
such as OLB should be actively sought even in immunocom-
promised patients when they do not respond to empirical ther-
apy. OLB may allow the common use of empirical antibiotics
to be tailored or even discontinued if they are not indicated.
Previous studies [4,7,8,10,11,16,17] have noted mortality
rates between 38 and 80% in patients with respiratory failure
who required OLB. Some of the studies cited a requirement
for mechanical ventilation as a strong predictor of poor
outcome [7,10,17,18]. In our series, the overall mortality rate
in the ICU was 50%. Although it is difficult to compare the
overall results because of different study designs and study
populations, the mortality in our study was at least comparable
with that in previous studies especially given the fact that a
requirement for mechanical ventilation was a poor prognostic
factor in many of the studies.
Twenty patients (56%) experienced complications related to
OLB; these consisted mainly of prolonged postoperative air
leakage. Minor complications, including transient hypotension
or arrhythmia during operation, occurred in five patients. Our
56% complication rate seems to be slightly higher than those
of the studies by Canver and Mentzer [11] (40%), Warner and
colleagues [7] (21%) and Flabouris and Myburgh [10] (17%).
This higher rate of complications is probably due to the fact
that all patients in this study were under mechanical ventilatory
support with high PEEP, which predisposes patients to pro-
longed air leakage. Despite the high incidence of prolonged air
leakage, no deaths were directly attributed to the complica-
tions from OLB and there was no significant difference in sur-
vival rate between those with complications and those without.
Comorbid diseases have been shown to be an important prog-
nostic factor in numerous studies in critically ill patients. The
CCS, developed by Charlson and colleagues [9] in 1987, is
the sum of 19 predetermined comorbidities given a weighted
score of 1, 2, 3, or 6 on the basis of the magnitude of the
adjusted relative risk associated with each comorbidity in a
Cox proportional hazards regression model. The CCS is a sim-
ple score to compute and objectively reflects the seriousness
of the combined influence of underlying conditions that may
contribute to survival [19]. In the present study, the CCS was
shown, in both univariate and multivariate analyses, to be an
important prognostic factor. In this study, 71% of those with-
out preexisting comorbidity survived, in contrast with only 32%
of those who had preexisting comorbidities. Patients without
comorbid diseases might have had a better capacity to with-
stand the inciting insult, making it easier for them to respond
to appropriate therapy. Interestingly, more than half of the sur-
vivors without preexisting comorbid diseases were diagnosed
with idiopathic interstitial pneumonitis (seven patients had
acute interstitial pneumonia, two had cryptogenic organizing
pneumonia, and one had fibrotic nonspecific interstitial pneu-
monia) and responded favorably to high-dose steroid therapy.
AIP is known to be a deadly disease with mortality rate of more
than 50% [20]. However, recent reports from our group and
others show that an early aggressive diagnostic approach,
mechanical ventilation with a lung-protective strategy, and the
early institution of high-dose steroid pulse therapy may
improve the clinical outcome [21,22].
The timing of OLB is controversial. In the present study,
although the duration of mechanical ventilation before the
OLB did not differ between the two groups, patients who
received OLB less than 1 week after the initiation of mechani-
cal ventilation were more likely to survive (63% versus 11%; P
= 0.018). In the literature there are several reports that also
suggest the benefit of early OLB. Warner and colleagues [7]
reported that the time from the onset of respiratory failure to
Table 4
Univariate analysis of variables associated with mortality
Variable P Odds ratio 95% CI
CCS 0.041 1.57 1.02–2.43
Number of organ dysfunctions 0.047 2.85 1.02–8.01
SOFAolb 0.013 1.55 1.10–2.19
SOFAmax 0.055 1.30 0.99–1.70
PaO2/FiO2 ratioon OLB day 0.023 0.985 0.973–0.998
Time to OLB, days 0.086 1.18 0.98–1.43
OLB complication 0.184 2.50 0.65–9.65
Immunocompromised status 0.146 0.31 0.67–1.50
CCS, Charlson age–comorbidity score; SOFAolb, SOFA (Sequential 
Organ Failure Assessment) score at the day of open lung biopsy; 
SOFAmax, maximum SOFA score; OLB, open lung biopsy; time to 
OLB, days from mechanical ventilation to OLB; CI, confidence 
interval.
Table 5
Multiple logistic regression analysis of variables associated 
with mortality
Variable P Odds ratio 95% CI
CCS 0.049 1.74 1.002–3.01
Number of organ dysfunctions 0.036 5.24 1.11–24.72
PaO2/FiO2 ratioon day of OLB 0.018 0.98 0.957–0.996
Only regressions with P < 0.05 are shown; all regression models 
include age, Charlson age–comorbidity score (CCS), number of 
organ dysfunctions on the day of open lung biopsy (OLB), PaO2/
FiO2 ratioon the day of OLB, days from mechanical ventilation to 
OLB, OLB-initiated treatment change, and development of 
mechanical complications after OLB. CI, confidence interval.Available online http://ccforum.com/content/11/4/R93
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OLB was significantly less in survivors (4.4 ± 2.9 days) than in
non-survivors (6.1 ± 3.6 days). McKenna and colleagues [23]
found that early OLB (average 3.6 days) benefited immuno-
compromised patients with a histological diagnosis of intersti-
tial pneumonia who were treated with steroids. In addition,
Lachapelle and Morin [16] observed that the institution of new
therapy was more beneficial in patients who underwent early
OLB compared with those undergoing late OLB. Coupled
with the fact that, in the present study, the PaO2/FiO2 ratio and
the SOFA score before OLB were significantly worse in the
non-survivor group, it seems to be important to perform a
biopsy early in the course of disease before irreversible lung
parenchymal damage or end-organ damage has set in. This
will give the patients the best chance to respond to appropri-
ate therapy. However, because urgent OLB without previous
diagnostic tests or empiric therapy does not provide any sur-
vival benefit over elective OLB [24], a prudent approach,
including initial stabilization and a trial of empirical treatment,
seems rational. Further studies on the optimal timing of OLB
are needed.
There are several limitations to this study. First, the selection
bias may have affected the result of our study. It is possible
that patients with more severe disease were excluded
because their condition precluded them from biopsy, or
patients may have died before biopsy was performed. Second,
its retrospective design may have affected the data for several
factors. For example, the impact of OLB on therapeutic modi-
fication may have been underestimated or even overestimated.
Third, the limited sample size in a heterogeneous patient pop-
ulation and the single-institution design of this paper limit the
generalization of our findings. Although a prospective rand-
omized study is able to draw powerful conclusions about the
role of OLB, it may be very difficult to perform prospective tri-
als in these critically ill patients. A more realistic and potentially
useful study design might be a well-constructed matched
case-control study, preferably multicentered. These studies
will allow us to make better decisions and possibly confirm the
benefit of early OLB.
Conclusion
OLB remains a clinically valuable tool in patients with respira-
tory failure of unknown etiology, even if it is severe enough to
require mechanical ventilatory support. OLB can provide a
specific diagnosis in many ventilator-dependent patients with
undiagnosed pulmonary infiltrate without life-threatening
complications. The early use of OLB seems to be useful in crit-
ically ill patients with isolated respiratory failure.
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